164 related articles for article (PubMed ID: 32446862)
1. Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma.
Lan W; Santofimia-Castaño P; Xia Y; Zhou Z; Huang C; Fraunhoffer N; Barea D; Cervello M; Giannitrapani L; Montalto G; Peng L; Iovanna J
Cancer Lett; 2020 Aug; 486():8-17. PubMed ID: 32446862
[TBL] [Abstract][Full Text] [Related]
2. ZZW-115-dependent inhibition of NUPR1 nuclear translocation sensitizes cancer cells to genotoxic agents.
Lan W; Santofimia-Castaño P; Swayden M; Xia Y; Zhou Z; Audebert S; Camoin L; Huang C; Peng L; Jiménez-Alesanco A; Velázquez-Campoy A; Abián O; Lomberk G; Urrutia R; Rizzuti B; Geli V; Soubeyran P; Neira JL; Iovanna J
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32780723
[TBL] [Abstract][Full Text] [Related]
3. NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.
Emma MR; Iovanna JL; Bachvarov D; Puleio R; Loria GR; Augello G; Candido S; Libra M; Gulino A; Cancila V; McCubrey JA; Montalto G; Cervello M
Cell Death Dis; 2016 Jun; 7(6):e2269. PubMed ID: 27336713
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of NUPR1 promotes cell death by coupling ER-stress responses with necrosis.
Santofimia-Castaño P; Lan W; Bintz J; Gayet O; Carrier A; Lomberk G; Neira JL; González A; Urrutia R; Soubeyran P; Iovanna J
Sci Rep; 2018 Nov; 8(1):16999. PubMed ID: 30451898
[TBL] [Abstract][Full Text] [Related]
5. Design of Inhibitors of the Intrinsically Disordered Protein NUPR1: Balance between Drug Affinity and Target Function.
Rizzuti B; Lan W; Santofimia-Castaño P; Zhou Z; Velázquez-Campoy A; Abián O; Peng L; Neira JL; Xia Y; Iovanna JL
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680086
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus X promotes hepatocellular carcinoma development via nuclear protein 1 pathway.
Bak Y; Shin HJ; Bak Is; Yoon DY; Yu DY
Biochem Biophys Res Commun; 2015 Oct; 466(4):676-81. PubMed ID: 26392315
[TBL] [Abstract][Full Text] [Related]
7. The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma.
Augello G; Emma MR; Azzolina A; Puleio R; Condorelli L; Cusimano A; Giannitrapani L; McCubrey JA; Iovanna JL; Cervello M
Cancer Lett; 2021 Oct; 519():250-262. PubMed ID: 34314755
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma.
Santofimia-Castaño P; Xia Y; Peng L; Velázquez-Campoy A; Abián O; Lan W; Lomberk G; Urrutia R; Rizzuti B; Soubeyran P; Neira JL; Iovanna J
Cells; 2019 Nov; 8(11):. PubMed ID: 31744261
[TBL] [Abstract][Full Text] [Related]
9. Response to the Letter to the editor regarding "Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma" by Jiong Lin.
Santofimia-Castaño P; Lan W; Xia Y; Zhou Z; Huang C; Barea D; Cervello M; Giannitrapani L; Montalto G; Peng L; Iovanna J
Cancer Lett; 2021 Mar; 500():161-162. PubMed ID: 33290870
[No Abstract] [Full Text] [Related]
10. Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer.
Chen CY; Wu SM; Lin YH; Chi HC; Lin SL; Yeh CT; Chuang WY; Lin KH
Theranostics; 2019; 9(8):2361-2379. PubMed ID: 31149049
[No Abstract] [Full Text] [Related]
11. NUPR1 inhibitor ZZW-115 induces ferroptosis in a mitochondria-dependent manner.
Huang C; Santofimia-Castaño P; Liu X; Xia Y; Peng L; Gotorbe C; Neira JL; Tang D; Pouyssegur J; Iovanna J
Cell Death Discov; 2021 Oct; 7(1):269. PubMed ID: 34599149
[TBL] [Abstract][Full Text] [Related]
12. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
13. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
[TBL] [Abstract][Full Text] [Related]
14. Targeting NUPR1-dependent stress granules formation to induce synthetic lethality in Kras
Santofimia-Castaño P; Fraunhoffer N; Liu X; Bessone IF; di Magliano MP; Audebert S; Camoin L; Estaras M; Brenière M; Modesti M; Lomberk G; Urrutia R; Soubeyran P; Neira JL; Iovanna J
EMBO Mol Med; 2024 Mar; 16(3):475-505. PubMed ID: 38360999
[TBL] [Abstract][Full Text] [Related]
15. TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction.
Zhu Y; Xu J; Hu W; Wang F; Zhou Y; Xu W; Gong W; Shao L
Gene; 2020 Aug; 753():144807. PubMed ID: 32461017
[TBL] [Abstract][Full Text] [Related]
16. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
17. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
18. Letter to the editor regarding "Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma".
Lin J
Cancer Lett; 2021 Feb; 499():1. PubMed ID: 33232790
[No Abstract] [Full Text] [Related]
19. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
Xiao Y; Sun L; Fu Y; Huang Y; Zhou R; Hu X; Zhou P; Quan J; Li N; Fan XG
BMC Cancer; 2017 Dec; 17(1):857. PubMed ID: 29246127
[TBL] [Abstract][Full Text] [Related]
20. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
